parvaquone

Parvaquone is a hydroxynaphthoquinone derivative used in veterinary medicine as an antiprotozoal agent. It is primarily indicated for the treatment of theileriosis (East Coast fever) in cattle, caused by protozoan parasites such as *Theileria parva* and *Theileria annulata*. The drug acts by interfering with the respiratory chain of the parasite, specifically by inhibiting the cytochrome bc1 complex (ubiquinol-cytochrome c reductase), which leads to a collapse of the mitochondrial membrane potential and parasite death. Viyash Life Sciences is developing parvaquone as part of its animal health pipeline, where it is currently in the preclinical stage.

Brand names

ClexonParvexon

Other names

2-hydroxy-3-cyclohexyl-1,4-naphthoquinone2-cyclohexyl-3-hydroxynaphtho-1,4-quinone